Global RNA-based Therapeutics Market

Report ID : 1151 | Published : 2021-07-27 | Pages: 140 | Format:

RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.

According to the latest research by InsightAce Analytic, the global market for RNA-based therapeutics was valued at US$ 1,756.5 Mn in 2019 and recording an exponential CAGR of 24.6% during the period of 2019-2030.  The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered.  The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market.  The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process. 

The Global RNA-Based Therapeutics Market is segmented based on drug class, therapeutic area, and region. Based on the drug class, the RNA-based therapeutics market is divided into RNA Aptamer, siRNA, Antisense RNA, and mRNA. Based on the therapeutic area, the market is segmented into  Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. On the basis of the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. North America is estimated to account for a leading position in the global RNA-based therapeutics market in 2019. The presence of a well-established healthcare system, high adoption of technically advanced tools, high government support, and the presence of a large number of companies focusing on RNA-based therapeutics are some of the key factors boosting the market growth in North America. In terms of growth rate, Asia Pacific is expected to register significant increase in the RNA- based therapeutics market during the estimated timeframe.

The key players of this market include Akcea Therapeutics Inc, Biogen Inc., Noxxon Pharma, Ophthotech Corporation, Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.), Antisense Therapeutics Ltd., Gene Signal, Gradalis, iCo Therapeutics, Lorus Therapeutics (Aptose Biosciences), miRagen Therapeutics, Mirna Therapeutics Inc, Marina Biotech, OncoGeneX Pharmaceuticals, Quark Pharmaceuticals, Pharmaxis Ltd, Rexahn Pharmaceuticals, Regulus Therapeutics, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., and Dicerna Pharmaceuticals. The growing strategic collaborations among the big biopharmaceutical companies to influence the platform of proprietary technology are expected to significantly generate immense opportunities for the growth of the market in the coming years.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global RNA- based Therapeutic Market Snapshot

Chapter 4. Global RNA- based Therapeutic Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers and Challenges

4.3. Trends

4.4. Clinical Trial/Pipeline Analysis

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Key Product Approvals

Chapter 5. Market Segmentation 1: Drug Class Estimates & Trend Analysis

5.1. Drug Class & Market Share, 2019 & 2026

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2027 for the following Drug Class:

5.2.1. RNA Aptamer

5.2.2. siRNA

5.2.3. Antisense RNA

5.2.4. mRNA

Chapter 6. RNA- based Therapeutic Market Segmentation 2: Therapeutic Area Estimates & Trend Analysis

6.1. Therapeutic Area Analysis & Market Share, 2019 & 2026

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2027 for the following Therapeutic Area:

6.2.1. Oncology

6.2.2. Genetic Disorder

6.2.3. Ophthalmology

6.2.4. Hematological Disorders

6.2.5. Acute Hepatic Porphyria (AHP)

6.2.6. Others

Chapter 7. RNA- based Therapeutic Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America RNA- based Therapeutic Market revenue (US$ Million) estimates and forecasts by Drug class, 2018-2027

7.1.2. North America RNA- based Therapeutic Market revenue (US$ Million) estimates and forecasts by Therapeutic Area, 2018-2027

7.1.3. North America RNA- based Therapeutic Market revenue (US$ Million) estimates and forecasts by country, 2018-2027

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe RNA- based Therapeutic Market revenue (US$ Million) by Drug class, 2018-2027

7.2.2. Europe RNA- based Therapeutic Market revenue (US$ Million) by Therapeutic Area, 2018-2027

7.2.3. Europe RNA- based Therapeutic Market revenue (US$ Million) by country, 2018-2027

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific RNA- based Therapeutic Market revenue (US$ Million) by Drug class, 2018-2027

7.3.2. Asia Pacific RNA- based Therapeutic Market revenue (US$ Million) by Therapeutic Area, 2018-2027

7.3.3. Asia Pacific RNA- based Therapeutic Market revenue (US$ Million) by country, 2018-2027

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America RNA- based Therapeutic Market revenue (US$ Million) by Drug class, (US$ Million)

7.4.2. Latin America RNA- based Therapeutic Market revenue (US$ Million) by Therapeutic Area, (US$ Million)

7.4.3. Latin America RNA- based Therapeutic Market revenue (US$ Million) by country, (US$ Million) 2018-2027

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA revenue RNA- based Therapeutic Market revenue (US$ Million) by Drug class, (US$ Million) 2018-2027

7.5.2. MEA revenue RNA- based Therapeutic Market revenue (US$ Million) by country, (US$ Million) 2018-2027

7.5.2.1. South Africa

7.5.2.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Akcea Therapeutics Inc

8.2.2. Biogen Inc.

8.2.3. Noxxon Pharma

8.2.4. Ophthotech Corporation

8.2.5. Olix Pharmaceuticals

8.2.6. GlaxoSmithKline Plc

8.2.7. Sanofi S.A

8.2.8. Alnylam Pharmaceuticals

8.2.9. Ionis Pharmaceuticals

8.2.10. Benitec Biopharma Ltd

8.2.11. Acuitas Therapeutics

8.2.12. Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

8.2.13. Silence Therapeutics Plc

8.2.14. Enzon Pharmaceuticals Inc

8.2.15. Antisense Therapeutics Ltd.

8.2.16. Bio-Path Holdings Inc.

8.2.17. Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)

8.2.18. Gene Signal

8.2.19. Gradalis

8.2.20. iCo Therapeutics

8.2.21. Lorus Therapeutics (Aptose Biosciences)

8.2.22. Marina Biotech

8.2.23. miRagen Therapeutics

8.2.24. Mirna Therapeutics Inc

8.2.25. OncoGeneX Pharmaceuticals

8.2.26. Quark Pharmaceuticals

8.2.27. Pharmaxis Ltd

8.2.28. Rexahn Pharmaceuticals

8.2.29. Regulus Therapeutics

8.2.30. Rxi Pharmaceuticals

8.2.31. Santaris Pharma A/S (Roche)

8.2.32. Sarepta Therapeutics

8.2.33. Sirnaomics Inc.

8.2.34. Dicerna Pharmaceuticals

8.2.35. Other Prominent Player

Global RNA-based Therapeutics Market Segmentation:

Global RNA-based Therapeutics Market by Drug Class

  • RNA Aptamer
  • siRNA
  • Antisense RNA
  • mRNA

Global RNA-based Therapeutics Market Based on Therapeutic Area

  • Oncology
  • Genetic Disorder
  • Ophthalmology
  • Hematological Disorders
  • Acute Hepatic Porphyria (AHP)
  • Others

Global RNA-based Therapeutics Market Based on Region

Europe RNA-based Therapeutics Market by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America RNA-based Therapeutics Market by Country

  • U.S.
  • Canada

Asia Pacific RNA-based Therapeutics Market by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America RNA-based Therapeutics Market by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa RNA-based Therapeutics Market by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients